Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III

Executive Summary

The ACR/ARHP Annual Meeting in San Diego offered new details from studies of new and existing therapies across a range of rheumatic diseases, from rheumatoid arthritis to rare diseases. Scrip shares notes here from interviews with Lilly, Ironwood, Corbus and Samumed.

Advertisement

Related Content

Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m
Pipeline Watch: Phase III Readouts For Cabozantinib, Topical Glycopyrronium
Lilly/Incyte's JAK Inhibitor Baricitinib Poised For FDA Approval After All
Duzallo Approval Opens Gout Opportunity For Ironwood
Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA
Corbus Cystic Fibrosis Data May Justify Longer, Larger Study
Lilly's Olumiant To Be EU's First RA JAK Inhibitor, But Pricing Is Key
ACR 2016 Roundup: Remicade Copy Not So Similar; Mixed Sirukumab Results; Corbus’s Resunab Surge
Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement
AZ's Gout Drug Gets FDA Go-Ahead With Safety Caveats

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099838

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel